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Prime and Boost Vaccination Elicit 
a Distinct Innate Myeloid Cell 
Immune Response
Jean-Louis Palgen1,2, Nicolas Tchitchek1,2, Jamila Elhmouzi-Younes1,2, Simon Delandre1,2, 
Inana Namet1,2, Pierre Rosenbaum1,2, Nathalie Dereuddre-Bosquet1,2, Frédéric Martinon1,2, 
Antonio Cosma  1,2, Yves Lévy2,3, Roger Le Grand1,2 & Anne-Sophie Beignon1,2
Understanding the innate immune response to vaccination is critical in vaccine design. Here, we 
studied blood innate myeloid cells after first and second immunization of cynomolgus macaques 
with the modified vaccinia virus Ankara. The inflammation at the injection site was moderate and 
resolved faster after the boost. The blood concentration of inflammation markers increased after both 
injections but was lower after the boost. The numbers of neutrophils, monocytes, and dendritic cells 
were transiently affected by vaccination, but without any major difference between prime and boost. 
However, phenotyping deeper those cells with mass cytometry unveiled their high phenotypic diversity 
with subsets responding differently after each injection, some enriched only after the primary injection 
and others only after the boost. Actually, the composition in subphenotype already differed just before 
the boost as compared to just before the prime. Multivariate analysis identified the key features that 
contributed to these differences. Cell subpopulations best characterizing the post-boost response were 
more activated, with a stronger expression of markers involved in phagocytosis, antigen presentation, 
costimulation, chemotaxis, and inflammation. This study revisits innate immunity by demonstrating 
that, like adaptive immunity, innate myeloid responses differ after one or two immunizations.
Many biological mechanisms involved with vaccination are still unclear and require further characterization. 
Several studies have highlighted the modulation of adaptive immunity by early innate immunity1, which may pro-
vide biomarkers to predict immune memory. Deciphering the mechanisms of the early innate immune response 
to vaccines will be valuable for optimizing them for protective immunity.
Innate myeloid cells are composed of mononuclear phagocytes, monocytes and dendritic cells (DCs), and 
granulocytes. They are involved in pathogen clearance, induction and resolution of inflammation, and antigen 
presentation2,3. They are often believed to react similarly to the first and subsequent pathogen encounters. Indeed, 
these cells are activated by germline-encoded pattern recognition receptors (PRR), are short-lived, except mac-
rophages, and unlikely to show memory features4. However, enhanced responsiveness to pathogen re-encounter, 
called trained immunity and related to epigenetic modifications, was reported for monocytes and macrophages5. 
The overall immune status also differs between the first and second pathogen encounters due to the presence of 
memory B and T cells and antibodies at the second encounter. In particular, antigen-antibody complexes are 
known to affect innate responses through the interaction of antibodies with Fc receptors found in most innate 
cells including granulocytes, monocytes/macrophages, and DCs6,7. This likely affects the behaviour of innate 
immune cells. However, this crosstalk between innate and adaptive immunity in the context of repeated vaccine 
injections, called prime-boost vaccine strategies, is still poorly understood, although they are widely used to 
increase the frequency of responders and enhance the immunogenicity and protective efficacy of vaccines8.
We studied the impact of vaccination on innate myeloid cells by immunizing cynomolgus macaques, which 
represent a relevant species for human vaccine research9,10. We used the modified Vaccinia virus Ankara (MVA), 
a smallpox vaccine, as a vaccine model to induce robust cellular and humoral immunity11. Unlike the vaccinia 
virus (VACV) from which it was derived, MVA requires a two-dose regimen to induce a strong antibody response 
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and provide full protection against VACV challenge in humans12,13 or monkeypox challenge in non-human pri-
mates14. MVA is also a potent vaccine vector currently being developed against several infectious diseases and 
cancers15. Many studies on cell tropism, innate immune activation and immune evasion used in vitro models16. 
However, a comprehensive overview of the mechanisms of MVA-induced immunity in vivo is still lacking.
Here, we developed a mass cytometry panel, focusing on innate myeloid cells, with the aim of identifying cell 
subphenotypes altered by vaccination. Mass cytometry is a promising technology for discovering cell subsets. It 
can unravel new mechanisms of the immunization process and help to design new vaccines. Currently, longitudi-
nal mass cytometry data analyses following immunization are scarce17,18. One of the main analysis challenge is the 
lack of appropriate pipelines. Here, we used the SPADE algorithm19 together with SPADEVizR20 to analyze our 
high-dimensional cytometry data. This analysis pipeline can be used for any kind of multidimensional cytometry 
data analysis, beyond the study of the dynamic of vaccine-induced immune responses or the study of vaccines 
modes of action. To make these complex data fully accessible to the scientific community, we publicly released 
them on the FlowRepository database and the Cytobank platform. We also created a website with interactive 
representations. We provide evidence of the phenotypic diversity of innate myeloid cells and of the qualitative and 
quantitative differences in their recruitment following MVA prime-boost immunization. This work constitutes 
the basis for future studies aiming to decipher how the differences in innate responses after one or two vaccine 
encounters depend on primary memory responses, and conversely how they affect the development of secondary 
memory responses.
Results
Changes in local and systemic inflammation following MVA prime and boost. Macaques were 
subcutaneously injected twice with MVA two months apart (Fig. 1). The specific antibody response developed 
by each animal was reported in a previous publication, and showed higher serum anti-MVA antibody titers after 
the boost than the prime18. We investigated in the very same animals the early responses to MVA injections. We 
tested if innate responses differed after prime and boost, as did adaptive immune responses. MVA injections 
induced low-grade, transient local inflammation at the injection site at early timepoints (Fig. 2a). Inflammation 
following prime was graded as 1.10 ± 0.22 and resolved by day 3 post-prime (D3PP), whereas it was milder 
(0.40 ± 0.55) and shorter after the boost.
The blood concentration of C-reactive protein (CRP) showed a transient peak at D1 post-injections (Fig. 2b). 
This peak was smaller after the boost than the prime (Supplementary Table S1). Among 24 tested soluble fac-
tors, only MCP-1, IL-6, and IP-10, were affected by vaccination, with concentrations differing significantly from 
pre-vaccination levels at two timepoints at least (Fig. 2c, Supplementary Figure S1 and Table S1). MCP-1 and IL-6 
were significantly induced after each MVA injection, with an earlier peak post-boost. We also detected high levels 
of IP-10 early after both the prime and boost. The area under the curve (AUC), as an approximation of exposure 
over time, showed that the cumulated concentration of IP-10 differed more between each immunization, than 
those of MCP-1 and IL-6. In addition, although non-significantly impacted, IFNγ, IL-10, IL-13, IL-15, IL-1Rα, 
IL-5, TGFα and TNFα concentrations tended to follow similar dynamics as MCP-1 and IP-10, whereas IL-1β 
tended to be closer to IL-6 (Figure S1).
Blood leukocytes following MVA injection. Changes in local and systemic inflammation after MVA 
prime-boost immunization were also accompanied by changes in blood cell concentration and composition. The 
absolute number of leukocytes increased significantly, as early as H3PP and H3PB, and rapidly returned to base-
line levels (Fig. 2d and Supplementary Table S2). However, in contrast to the macroscopic local reaction (Fig. 2a), 
leukocytes AUC were similar after each vaccine injection. Note that these transient post-injections increases 
of blood cell counts were specific to vaccine injections. Indeed, buffer injection only moderately impacted leu-
kocytes counts, and at a statistically significant lower level at H6 and D1 as compared to MVA (Supplementary 
Figure S2).
Figure 1. Experimental design and analysis pipeline. Five adult cynomolgus macaques were immunized, 
two months apart with MVA HIV-B at a dose of 4 × 108 PFU injected subcutaneously. Blood was collected 
longitudinally at the indicated timepoints, hours (H) or days (D), post-prime (PP) and post-boost (PB), for 
Luminex, ELISA, and mass cytometry analyses to evaluate the plasma concentrations of cytokines and CRP 
and to phenotype in deep innate myeloid cells. Local inflammation was also scored at the indicated timepoints. 
Baseline samples were collected 21 and 19 days before the first vaccine injection for plasma soluble factors and 
single cell mass cytometry analysis, respectively, as well as just before the first immunization at H0PP. A blood 
draw was also collected just before the boost at D58PP/H0PB.
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Figure 2. Local inflammation, systemic inflammation and complete blood count. (a) Individual local 
inflammation scores, as well as mean ± standard deviation, are represented over time. Local skin reactions 
at the site of the subcutaneous MVA injection were scored from 0 to 4, based on the evaluation of edema and 
erythema. 0: no swelling and normal color; 1: slight swelling with indistinct border and light pink erythema; 2: 
defined swelling and bright pink erythema, both with distinct borders; 3: defined swelling with a raised border 
(<1 mm) and bright red erythema with a distinct border; 4: pronounced swelling with a raised border (>1 mm) 
and dark red erythema. (b) The concentration of C-reactive protein (CRP), as well as mean ± standard 
deviation, was assessed in plasma before and after MVA immunization. Individual levels are shown. (c) The 
concentrations of MCP-1, IL-6, and IP-10 were measured in plasma after the first and second MVA injection. 
Individual concentrations are shown. The individual AUC after the prime (H3-D14PP) and boost (H3-D14PB) 
were computed and compared using a permutation test. The mean PP and PB AUC, and the p-values after the 
permutation test to compare them are indicated. The red arrows indicate prime and boost injections. The dotted 
line indicates the median concentrations for each cytokine at baseline (D-21PP and H0PP). (d) Blood leukocyte 
counts were followed over time. Individual absolute numbers are shown. Leukocyte counts were missing for 
macaques BB078 and BB231 at D8PB.
www.nature.com/scientificreports/
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Leukocytes correspond to the sum of several immune cell types with heterogeneous phenotypes and func-
tions. Thus, we used mass cytometry to more deeply phenotype blood immune cells over time after immuniza-
tion, focusing on innate myeloid cells (Fig. 3a and Supplementary Table S3). We developped an analysis pipeline 
adapt to longitudinal mass cytometry data. We used three successive complementary clusterings, which led to 
Figure 3. Mass cytometry. (a) Fixed leukocytes were stained with a panel of Abs designed to analyze innate 
myeloid cells by mass cytometry. Thirty-two targeted markers and their associated biological functions are 
indicated. (b) The steps of the mass cytometry data analysis are displayed. As the first analysis step, single cells 
from FCS files were grouped into clusters sharing similar phenotype using the SPADE algorithm. Clusters 
were annotated on the resulting SPADE tree based on the expression of a set of 10 markers, and granulocytes 
and monocytes-DCs were identified. As the second analysis step, clusters of granulocytes and monocytes-
DCs sharing the same categories of marker expression were regrouped into phenotypic families. As the third 
analysis step, phenotypic families sharing the same abundance profiles were clustered into kinetic families. 
Finally, after these three successive clusterings, and as the last analysis step, discriminant analyses were used 
to determine which kinetic families best distinguished between post-prime and post-boost immune response, 
and to define the phenotypic signature of each response. (c) Mass cytometry data were analyzed using 
SPADE. The topology of the SPADE tree is shown. This tree was built using all samples (all macaques and all 
timepoints). Only the topology of the tree is displayed where each node corresponds to a cell cluster. It does 
not correspond to a particular sample and size of node is not related to their cell content. Clusters with similar 
phenotypes are linked using a minimal spanning tree approach. SPADE clusters were annotated and colored 
with respect to the expression of markers indicated in Supplementary Figure S3 and as follows: neutrophils 
(CD66+), basophils (CD66-CD123+HLA-DR−), monocytes (CD14+HLA-DR+), cDCs (CD14−HLA-
DR+CD11c+CD16+), inflammatory cDCs/non-classical monocytes (CD14+HLA-DR+CD11c+CD16+), pDCs 
(CD123+HLA-DR+), uncharacterized APCs (CD3−CD8−CD14−CD20−CD11c−CD16−CD123−HLA-DR+), B 
cells (CD20+HLA-DR+), T cells (CD3+), and NK cells (CD3−CD8+). Granulocytes were defined as neutrophils 
and basophils, and monocytes-DCs as monocytes, cDCs, pDCs, inflammatory cDCs/non-classical monocytes 
and uncharacterized APCs.
www.nature.com/scientificreports/
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the identification of cell clusters, phenotypic families and kinetic families respectively. They were followed by the 
automated identification and ranking of the cell populations and markers that best discriminate the responses 
after the first and the second immunizations (Fig. 3b).
Mapping the phenotypic diversity of blood granulocytes, monocytes, and DCs. We first used 
the SPADE algorithm19 to identify clusters of leukocytes with similar phenotypes within the whole dataset (all 
animals and all timepoints). SPADE was optimally parameterized and resulted in the partition of leukocytes 
into 600 clusters (Supplementary Figure S3 and Tables S5-S6). The stringency of our analysis likely resulted in 
‘over-clustering’, generating many artificial cell subpopulations. However, we and others consider ‘over-clustering’ 
to be less misleading than ‘under-clustering’, particularly as an initial step21.
We annotated each cluster based on the SPADE tree and the expression of a restricted set of markers 
(Fig. 3c and Supplementary Figure S4). We identified 252 clusters of neutrophils (CD66+), seven of baso-
phils (CD66−HLA-DR−CD123+), 76 of monocytes (HLA-DR+CD14+), 47 of CD11c+ cDCs latter referred as 
cDCs (HLA-DR+CD14−CD11c+), four of inflammatory cDCs/non-classical monocytes (HLA-DR+CD14+C
D11c+CD16+), two of plasmacytoid dendritic cells (pDCs, HLA-DR+CD123+), and nine of uncharacterized 
antigen-presenting cells (APCs, HLA-DR+CD123−CD14−CD11c−CD16−). We focused our analysis on these 
innate myeloid cells. We also identified 61 clusters of B cells (HLA-DR+CD20+), 115 of T cells (CD3+), and 27 of 
NK cells (CD3−CD8+), which were not further studied.
Note that we previously reported that cynomolgus macaque cDCs expressed CD16 at a high and homogene-
ous level in cynomolgus macaques10. The use of CD11c to define cDCs in macaque is controversial. In rhesus and 
cynomolgus macaques, it has been shown that CD14highCD16high and CD14low/midCD16high monocytes expressed 
higher levels of CD11c than cDCs22,23. In contrast, cynomolgus macaques cDCs were recently defined based on 
their CD11c expression, although it did not allow to fully segregate cDCc into cDC1s and cDC2s by itself and 
other markers were required24. We annotated clusters that shared common features with monocytes and cDCs 
(HLA-DR+CD14+CD11c+CD16+) as inflammatory cDCs/non-classical monocytes, given that there is no con-
sensus yet for cynomolgus macaques DCs/monocytes subsets and that we lacked the critical markers to fully 
discriminate cDC1s and cDC2s.
We analyzed the dynamics of granulocytes (comprising neutrophils and basophils) (Supplementary Figure S5a 
and Supplementary Table S2) and monocytes-DCs (comprising monocytes, cDCs, pDCs, inflammatory cDCs/
non-classical monocytes and uncharacterized APCs) (Supplementary Figure S5b and Supplementary Table S2) in 
response to each vaccine injection. We calculated the absolute number of each cell population instead of using the 
percentage of parent cells because leukocyte counts highly varied during vaccination. Granulocytes represented 
the most abundant population among leukocytes at all timepoints and showed two significant rapid, transient 
increases, peaking at H6PP and H6PB. Granulocyte counts returned to baseline levels faster after the boost than 
the prime. However, their AUC were similar after each vaccine injection. The absolute number of monocytes-DCs 
also showed a first peak at H6-D1PP and a second, smaller one at H6PB, but without significant differences 
between the two immunizations.
The local macroscopic reaction likely reflected the recruitment of cells from the circulation and bone marrow 
to the vaccine injection site25. We next deeply characterized the phenotype of granulocytes and monocytes-DCs 
to reconcile the difference in local and systemic inflammation between prime and boost with the absence of major 
differences in blood cell counts on the scale of leukocytes, granulocytes, and monocytes-DCs.
SPADE clustering was followed by a second clustering (Fig. 3b). Hierarchical clustering was performed 
at both cell cluster and marker levels to better visualize the similarities between cell cluster phenotypes and 
marker co-expression patterns. We generated two categorical heatmaps to visualize phenotype of each cell clus-
ter at a glance, as oppposed to SPADE trees: one heatmap for the granulocytes compartment and one for the 
monocytes-DCs compartment (Fig. 4). Heatmaps represent the phenotypic diversity within the dataset, but not a 
particular sample and, in no case, a particular timepoint. They are not snapshots.
Clusters sharing similar phenotypes as measured by a close proximity on the heatmap cluster dendrogram, 
were gathered into phenotypic families. This analytical strategy prevents inaccurate interpretations due to poten-
tial ‘over-clustering’. Indeed, clusters may actually account for different stages of activation or maturation within 
a cell subpopulation, whereas phenotypic families may represent actual subpopulations.
For the granulocytes compartment (Fig. 4a and http://data.idmitcenter.fr/MVA-innate-myeloid/ for inter-
active heatmaps), 21 phenotypic families were distributed across five superfamilies, highlighting the richness 
of their phenotypes. The first superfamily A represented highly activated neutrophils (CD66mid/highCCR7highC-
D32highCD45highCD11bhigh) and comprised phenotypic families 9, 16, 6, 15, and 2. The second superfamily B rep-
resented intermediately activated neutrophils (CD66mid/highCCR7midCD32midCD45midCD11bmid) and contained 
phenotypic families 3, 7, and 5. The third superfamily C represented poorly activated neutrophils (CD66low/midC-
CR7lowCD32lowCD45lowCD11blow) and comprised phenotypic families 4, 13, 11, 19, and 1. Strikingly, phenotypic 
family 13 and a subpart of family 2 showed high expression of CD14. CD14high neutrophils were described in the 
literature26 but their functional importance remains to be characterized.
The fourth superfamily D corresponded to CD4mid/highCD23highCD11chigh neutrophils and comprised phe-
notypic families 17, 12, and 10. The expression of CD4 and CD23 correlated among granulocytes (R = 0.78) 
(Supplementary Figure S6a). CD4 expression was previously reported in neutrophils27 but was not functionally 
characterized. In addition, the expression of CD23 and CD11c by neutrophils was shown to be linked to inflam-
mation28–30. Family 17 showed a high level of several markers, including CD123, CD14, CD86, CD16, IP-10, 
MCP-1, CD4, CD3, CD8, IL-4, and IL-6. This phenotypic signature may be due to nonspecific staining or to 
the presence of contaminating cell doublets. It may account for the unexpected strong correlation between the 
expression of CD3 and CD8 (R > 0.75). One cluster (cluster 416) was annotated as basophils, based on the SPADE 
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Figure 4. High phenotypic diversity of granulocytes and monocytes-DCs. Hierarchical clustering of markers 
and (a) granulocytes or (b) monocytes-DCs clusters were computed and represented as heatmaps. Each line of 
the heatmaps corresponds to one cell cluster and each column to one marker. Marker and cluster dendrograms 
were generated to bundle clusters with similar phenotypes and markers with similar expression patterns. Based 
on the cluster dendrograms, 21 groups of clusters, called phenotypic families, which are arbitrarily colored 
and numbered using Arabic numerals, were identified for both granulocytes and monocytes-DCs. Groups of 
phenotypic families defining superfamilies were framed with bold lines, and labeled with capital letters. When 
describing the heatmaps, phenotypic families are always listed from top to bottom, with ‘;’ to separate them 
according to their superfamily origin. SPADE clustering markers are written in bold. Interactive heatmaps are 
available at http://data.idmitcenter.fr/MVA-innate-myeloid/.
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tree. Indeed, it showed far higher CD123 expression than its neutrophil counterparts (Supplementary Figure S3), 
confirming the relevance of our SPADE tree annotation.
The fifth superfamily E included basophils and neutrophils and comprised phenotypic families 20, 21, 14, 8, 
and 18. Family 18 contained six clusters of CD66lowCD123highIL-4high basophils and one cluster (cluster 598) anno-
tated as neutrophils, based on the SPADE tree. Although high, its CD123 expression was lower than in basophils 
clusters (Supplementary Figure S3), confirming the relevance of our SPADE tree annotation. Families 20, 21, and 
14 corresponded to neutrophils, displaying a unique phenotype characterized by varying expression of CD16, 
CD11c, CD45, CCR5, CXCR4, MCP1, IFNα, and IFNγ. CD16 and CD11c expression correlated with each other 
in granulocytes (R = 0.77) (Supplementary Figure S6a), suggesting that phenotypic families 20 and 21 could be 
highly activated neutrophils and linked to inflammation or modulation of the immune response, with potential 
IFNα production31,32.
We identified four phenotypic families (17, 15, 19, and 1) scattered throughout distinct superfamilies, as well 
as two clusters of basophils (cluster 577 and 598), expressing a high level of CD64 and IL-1α. The presence of 
these two markers highly correlated (R = 0.82) with each other (Supplementary Figure S6a). The expression of 
CD64 in neutrophils was described as a biomarker of infection33,34, whereas IL-1α was shown to be important for 
the recruitment of neutrophils and other myeloid cells35,36. In addition, there was a high correlation between IL-12 
and CCR7 expression among granulocytes (R = 0.75) (Supplementary Figure S6a). This association suggests a 
more mature and activated phenotype, since CCR7 was shown to be involved in granulocyte activation37 and 
IL-12 is also key to neutrophil activation38.
In the monocytes-DCs compartment, 21 phenotypic families were also identified (Fig. 4b and http://data.
idmitcenter.fr/MVA-innate-myeloid/ for interactive heatmaps). These phenotypic families segregated into three 
superfamilies. The first superfamily F corresponded to cDCs (phenotypic families 33, 40, 27, 39, 29, 37 and 
26). The second superfamily G comprised pDCs, CD14lowmonocytes, and uncharacterized APCs (phenotypic 
families 31, 30 and 28). Finally, the third superfamily H was composed of monocytes and inflammatory cDCs/
non-classical monocytes (phenotypic families 38, 42, 24, 23, 35, 41, 32, 36, 22, 25 and 34).
As expected, cDCs and monocytes clearly segregated apart from each other within distinct superfamilies, the 
former expressing a high level of CD16, CD11c and CD11a, whereas the latter expressed a high level of CD14. 
CD14+CD16+HLA-DR+ inflammatory cDCs/non-classical monocytes (phenotypic family 32) segregated with 
monocytes.
CD11a, CD11c, and CD16 expression highly correlated with each other (R > 0.75 for each correlation) 
(Supplementary Figure S6b), confirming this characteristic of macaque cDCs. cDCs showed varying expres-
sion patterns for CCR5, CXCR4, CD64 and HLA-DR. Phenotypic families 29 and 37 consisted of highly acti-
vated HLA-DRhighCCR5mid/highCXCR4mid/high cDCs. Phenotypic families 33, 40, 27, 39 and 26 regrouped less 
activated (potentially immunosuppressive) HLA-DRlow/mid cDCs. Phenotypic families 33, 40, 27 and 39 were 
CCR5highCXCR4high, whereas family 26 was CCR5lowCXCR4low suggesting different recruitment abilities to the site 
of inflammation. In addition, phenotypic families 27 and 39 were CD64low whereas phenotypic families 33 and 40 
were CD64high indicating different antibodies binding capacities and suggesting they could be monocytes-derived 
cDCs39.
Besides, CD14, CD11b, and CD32 expression correlated with each other (R > 0.75 for each correlation) 
(Supplementary Figure S6b), confirming these monocyte-specific features. Surprisingly, CD86 also correlated 
with CD14 (R = 0.81) and CD32 (R = 0.82) (Supplementary Figure S6b), suggesting that this costimulatory 
molecule is poorly expressed on macaque blood cDCs, in contrast to monocytes. Overall, monocytes displayed 
varying expression of CD32, CD11b, and CD45. Phenotypic families 36 and 22 regrouped likely immature and 
potentially immunosuppressive HLA-DRlow monocytes. Phenotypic families 25 and 34 regrouped poorly acti-
vated CD32lowCD11blowHLA-DRhigh monocytes. Phenotypic family 32 consisted solely of inflammatory cDCs/
non-classical monocytes. Phenotypic families 23 and 35 consisted of moderately to highly activated CD32mid/
highCD11bmid/highCD11amidHLA-DRhigh monocytes. Finally, phenotypic families 38, 42 and 24 consisted of highly 
activated CD32highCD11bhighCD11ahighHLA-DRhigh monocytes. Phenotypic family 41 consisted of IL-12 produc-
ing CD66highCCR7highHLA-DRhigh monocytes.
In the second superfamily G, clusters expressed a high level of HLA-DR and segregated closer to monocytes 
than cDCs. Phenotypic families 31 and 30, labeled as uncharacterized APCs, contained CCR5highCXCR4highIP-
10high cells. These cells could correspond to activated monocytes which have downregulated CD14 and CD11b, 
a feature linked to activation and macrophage differentiation40,41. Family 28 contained two CD123highIL-
4mid clusters, labeled as pDCs (clusters 360 and 75), and two clusters labeled as monocytes, that were solely 
HLA-DRhighCD14low (clusters 476 and 362). Interestingly, the two clusters of pDCs differed by the expres-
sion of CCR5 and CXCR4, suggesting different recruitment and/or maturation abilities. Most pDCs were 
CCR5highCXCR4high but surprisingly IFNαlow (Supplementary Figure S3). This may be explained by the ex vivo 
staining without cytokine secretion inhibitors. Indeed, whole blood was extemporaneously fixed after sampling 
and without blocking cytokine secretion to avoid granulocytes alteration. Using these settings, we may not cap-
ture the production of cytokines whose concentrations did not reach a certain threshold or that were secreted 
very fastly. Alternatively, blood pDCs may be non-activated and thus would not produce IFNα42. In addition, 
we may not capture all the pDC diversity due to the low amount retrieved from macaque blood (Supplementary 
Figure S7).
Our data show a high degree of phenotypic diversity among blood granulocytes and monocytes-DCs with 
several degrees of activation/maturation. We uncovered potential novel subsets with newly described marker 
co-expression. Such diversity was captured because of the high number of markers specifically targeting innate 
myeloid cells and the high number of clusters defined. However, this diversity was also captured because our orig-
inal longitudinal dataset was composed of samples collected at steady state, before or long after immunization, 
outnumbered by samples collected early after immunization, during acute inflammation.
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Distinct subphenotypes respond to first and second immunizations. The categorical heatmaps that 
we generated provided good information on cell subsets phenotypic diversity within the dataset. But these still 
pictures did not provide information on cell subset frequencies, or their continuous or transient presence. To go 
beyond these pictures, we studied the impact of MVA injections on the abundance of cells from the different phe-
notypic families with respect to animals and time. Various abundance profiles depending on the phenotypic fam-
ilies were found and the post-prime and post-boost transient expansions were not always equal (Supplementary 
Figures S8 and S9). Using a third clustering step (Fig. 3b), the 21 phenotypic families of granulocytes and 21 
phenotypic families of monocytes-DCs were gathered together into 12 kinetic families sharing similar abun-
dance profiles (Fig. 5, Supplementary Figures S9, S10 and Supplementary Table S4). The correspondence between 
kinetic families and phenotypic families is given in Table 1 and in Supplementary Figures S9 and S10, but more 
simply thanks to interactive heatmaps on http://data.idmitcenter.fr/MVA-innate-myeloid/.
Strikingly, although there was no significant difference between prime and boost leukocytes AUC (Fig. 2d), 
nor granulocyte AUC or monocytes-DCs AUC (Supplementary Figure S5), the dynamics of five of the 12 kinetic 
families displayed significant differences (measured with AUC) after the prime and boost. Poorly to moderately 
activated neutrophils (granulocytes phenotypic families 14, 8, 4, 13, 11, 19, 1, 3), as well as uncharacterized APCs 
(monocytes-DCs phenotypic family 30) belonged to kinetic families I and III, and were mostly present in the 
blood after the prime (Fig. 5a and Supplementary Figure S10). The enrichment of cells from kinetic family III was 
not as transient as those of cells from kinetic family I.
Conversely, moderately to highly activated neutrophils (granulocytes phenotypic families 12, 9, 16, 6, 15, 
2, 7, and 5), activated monocytes (monocytes-DCs phenotypic family 24, 35, and 41), inflammatory cDCs/
non-classical monocytes (monocytes-DCs phenotypic family 32), and CCR5highCXCR4highcDCs (monocytes-DCs 
phenotypic family 39 and 29) composed kinetic families II, IV, VI and X, and were mostly present after the boost 
(Fig. 5a and Supplementary Figure S10). We observed two successive waves of enrichment for kinetic families IV, 
VI, and X. The second wave was especially late for family IV.
Neutrophils (granulocytes phenotypic families 20, 21, 17, and 10), monocytes (monocytes-DCs pheno-
typic families 38, 42, 23, 36, 22, 25, and 34), uncharacterized APCs (monocytes-DCs phenotypic family 31), 
and HLA-DRlowcDC (monocytes-DCs phenotypic family 27) were part of kinetic families V, VIII, and IX, and 
were both affected after the prime and boost, albeit differently (Fig. 5a and Supplementary Figure S10). For 
kinetic family V, there was only one rapid and transient increase at D1PP, whereas there were two rapid and 
transient increases at D1 and D8PB, the second being stronger. Kinetic family VIII showed an increase at H6-D1 
post-injections with a stronger and faster increase after the prime. Kinetic family IX displayed a rapid and tran-
sient increase at H6 post-injections, the PP peak being larger.
There was no significant impact of MVA immunizations on cell abundance for the basophils (granulocyte phe-
notypic family 18), pDCs, CD14low monocytes (monocytes-DCs phenotypic family 28), as well as HLA-DRlow and 
CD64high cDCs (monocytes-DCs phenotypic family 33, 40, 37 and 26) belonging to the three remaining kinetic 
families VII, XI, and XII (Fig. 5a and Supplementary Figure S10). Cells from these kinetic families were scarce.
To provide a more general picture of the distribution of the different phenotypic families and its evolution, pie 
charts were displayed at key timepoints: just before the prime (H0PP), just before the boost (H0PB), at the acute 
peak of the innate immune response (H6PP and H6PB), and at later timepoints (D14PP and D14PB) (Fig. 5b,c). 
This representation highlighted that, strikingly, the composition in phenotypic families already differed just 
before the boost as compared to just before the prime. Also, at D14PP, granulocyte counts were back to baseline, 
but the repartition in phenotypic families was still closer to H0PP than H0PB, suggesting that innate myeloid 
responses were not over at D14 post-injection and that a switch in phenotype occurred later, between D14PP 
and D58PP/H0PB. Differences between prime and boost were not as pronounced within the monocytes-DCs 
compartment.
Biological relevance of kinetic families. Before going further, we addressed the relevance of the kinetic 
families identified through three successive clustering steps (Fig. 3b). We assessed whether there were any associ-
ations between a direct measurement of inflammation and the enrichment of these kinetic families.
We used a linear regression analysis to predict IP-10 concentration based on kinetic family abundances. We 
chose IP-10 because it differed the most in AUC between prime and boost. IP-10 was also proposed as a candi-
date biomarker for diagnosis, prognosis, or responsiveness to therapy for several inflammatory and infectious 
diseases43. The prediction highly fit our observations (Fig. 6a,b), validating the computational analysis designed 
to define kinetic families. Linear regression showed that IP-10 concentrations positively correlated with the abun-
dance of two kinetic families, III and VI (Fig. 6c), corresponding to neutrophils enriched only after the prime 
(granulocyte phenotypic families 8; 4 and 13; and 3) and only after the boost (granulocyte phenotypic families 
16 and 2) (Table 1). These neutrophils surprisingly did not produce IP-10, in contrast to granulocyte phenotypic 
family 17. It is possible that plasma IP-10 was mainly released by cells present at the MVA injection site rather 
than in blood.
Key phenotypic features that discriminate between post-prime and post-boost immune 
responses. Our findings show that innate myeloid immune responses strongly differed between prime and 
boost, but it did not take into account the absolute number of cells in each kinetic family. Thus, we performed a 
Multidimensional Scaling (MDS) analysis to represent the similarities between all samples, based on cell abun-
dances of each kinetic family.
H3PP, H6PP, D1PP, and H6PB clearly segregated apart from most timepoints, which were close to one another 
in the MDS representation (Fig. 7a). H3PP, H6PP and D1PP were also distant from H6PB. This segregation con-
firmed that innate myeloid responses differed between prime and boost. It also showed that the innate immune 
response was strongly affected during three timepoints post-prime and only a single timepoint post-boost.
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Figure 5. Different enrichment of innate myeloid cells after first and second immunizations. (a) Phenotypic 
families sharing similar abundance profiles were gathered into kinetic families after hierarchical clustering based 
on abundance profiles with the Pearson correlation. Twelve kinetic families were defined and arbitrarily numbered 
from I to XII. They were further regrouped based on their kinetic pattern with an enrichment essentially post-prime, 
essentially post-boost, both after the prime and boost, or no or heterogeneous enrichment after each immunization. 
The mean abundance among the five animals is displayed ± standard deviation. The individual AUC after the prime 
(H3-D14PP) and boost (H3-D14PB) were calculated for each kinetic family and compared using a permutation test. 
The p-values are indicated and considered to be significant when p ≤ 0.01. Note that the scale of the Y-axis is specific 
to each kinetic family. The red arrows indicate the prime and boost injections. (b,c) Composition in phenotypic 
families of the granulocytes (b) and monocytes-DCs (c) compartment at H0PP, H6PP, D14PP, H0PB, H6PB and 
D14PB for each macaque. The size of the pie chart is proportional to the cell concentration. The color-code for each 
phenotypic families is identical for the pie-charts and the heatmaps.
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We further identified the main features that differed between the post-prime and post-boost immune response 
by using a Least Absolute Shrinkage and Selection Operator (LASSO) approach (Supplementary Figure S11). This 
approach allowed to statistically select the kinetic families that best characterized the post-prime or post-boost 
immune response. In particular, it permitted to exclude, in a statistical manner, kinetic families that were not 
impacted by vaccination or were impacted similarly at both immunizations. Among the twelve kinetic families, 
eight (I, II, III, IV, V, VI, X and XI) were sufficient to fully discriminate between the two responses (Fig. 7b). 
Linear discriminant analysis (LDA) allowed us to score their contribution to post-prime and post-boost cate-
gory and gave a statistical criterion to classify the selected kinetic families in post-prime or post-boost signature 
(Fig. 7c). This analysis revealed that the main components of the post-prime immune response were kinetic 
families III, XI, and, to a lesser extent, I. They were composed of granulocyte phenotypic families 14 and 8; 4 and 
13; 11, 19, and 1; and 3 (poorly to moderately activated neutrophils) and monocytes-DCs phenotypic families 
30 and 28; and 37 and 26 (pDCs, CD14low monocytes, uncharacterized APCs, and cDCs). Conversely, the main 
components of the post-boost immune response were kinetic families V, II, IV, X, and, to a lesser extent, VI. They 
were composed of granulocyte phenotypic families 20; 17, 12, and 10; 9, 16, 6, 15, and 2; and 7 and 5 (moderately 
to highly activated neutrophils) and monocytes-DCs phenotypic families 42, 24, 35, 41, 32 and 25; and 39 and 29 
(monocytes, including inflammatory cDCs/non-classical monocytes, and cDCs) (Table 1).
We identified markers differentially expressed by cell populations that best discriminated the post-prime from 
the post-boost response, based on a Kolmogorov-Smirnov distance criterion (Supplementary Figure S12). The 
expression of CD11b, CD66, CD45, IL-8, CD32, CD11a, HLA-DR and IL-10, and to a lesser extent CCR7, was 
higher in neutrophils found in abundance in blood after boost than after prime (Fig. 7d and Supplementary 
Figure S12a). CCR5, CXCR4, CD11c, CD16, CD45, IL-12, HLA-DR, and CD11b were more highly expressed by 
cDCs enriched after the boost than those enriched after the prime (Fig. 7e and Supplementary Figure S12b). To 
a lesser extent, CD11a expression was also associated with cDCs enriched after the boost. Finally, CD32, CD11b, 
HLA-DR, CD11a, CD14, CD45, IP-10, and IL-12 expression was higher in monocytes involved in the post-boost 
response than those participating in the post-prime response (Fig. 7f and Supplementary Figure S12c).
In conclusion, innate myeloid subpopulations that distinguished the post-boost from the post-prime response, 
and that were actually already present at the time of the boost, showed higher expression of several activation/
maturation markers. Among them, three markers were shared by neutrophils, cDCs, and monocytes: CD45, 
CD11b and HLA-DR.
Discussion
We report a mild local reactogenicity to subcutaneous MVA injection in macaques, which was weaker and more 
rapid after the second injection. Plasma CRP and IP-10 concentrations, used as systemic inflammation readouts, 
were also more attenuated after the boost. We observed an early and transient enrichment of innate myeloid cells 
in the circulation both after the prime and the boost. Strikingly, at the level of each compartment (granulocytes 
and monocytes-DC), no major differences in cell abundance intensity or kinetics were observed between the two 
injections. Qualitative differences between the blood innate myeloid cell responses after one or two immuniza-
tions were only observable after deep phenotyping using mass cytometry combined with an analysis pipeline 
consisting of three successive clusterings specifically developed for longitudinal multidimensional data, and a 
final discriminant analysis. Neutrophils, monocytes and DCs, which expanded transiently at each immunization, 
were not composed of the same cell subpopulations. While circulating innate myeloid cells rapidly returned to 
baseline level in terms of their number after prime, their sub-phenotype composition was modified over time, 
Kinetic 
family
Composition
Kinetic patternPhenotypic family Cell population
I Granulocytes 14; 11, 19, and 1  Monocytes-DCs 30 Neutrophils, including poorly to moderately 
activated neutrophils and uncharacterized APCs Post-prime enrichment
III Granulocytes 8; 4 and 13; 3
II Granulocytes 6 and 2; 7 and 5  Monocytes-DCs 35 and 41 Neutrophils, including moderately to highly 
activated neutrophils, highly activated monocytes, 
CCR5highCXCR4highcDCs, and inflammatory cDCs/
non-classical monocytes
Post-boost enrichmentIV Granulocytes 9 and 15
VI Granulocytes 12 and 16
X Monocytes-DCs 24 and 32; 39 and 29
V Granulocytes 20; 17 and 10  Monocytes-DC 42 and 25
Neutrophils, poorly to highly activated monocytes, 
HLA-DRlowcDCs, and uncharacterized APCs
Post-prime and post-boost 
enrichmentVIII Granulocytes 21  Monocytes-DCs 38, 36 and 22
IX Monocytes-DCs 23 and 34; 31; 27
VII Granulocytes 18
Basophils, pDCs, CD14lowmonocytes, and cDCs 
including HLA-DRlowand CD64highcDCs
No/heterogeneous 
enrichmentXI Monocytes-DCs 28; 37 and 26
XII Monocytes-DCs 33 and 40
Table 1. Correspondence between kinetic and phenotypic families. For each kinetic family, its composition in 
terms of phenotypic families (listed from top to bottom from the corresponding heatmaps (Fig. 4) and separated 
by “;” to designate their being from different superfamilies) and its main cell populations and phenotypes, as 
well as its kinetic pattern, as classified in Fig. 5a, are indicated.
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and finally different at the time of the boost. Some subsets expanded after each immunization, whereas others 
were enriched primarily after the prime or the boost. Neutrophils, monocytes, and DCs responding to the second 
injection expressed higher levels of CD45, HLA-DR, Fc receptors CD16 and CD32, integrins CD11a, CD11b, and 
CD11c, some of which form complement receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18), chemokine 
receptors CCR5 and CXCR4, pro-inflammatory cytokines IL-8, IL-12, and IP-10, and anti-inflammatory cytokine 
IL-10. Thus, local and systemic inflammation after the boost was attenuated with respect to after the prime, 
whereas as many innate myeloid cells were recruited after the boost as after the prime. However cells mobilized 
after the boost were more activated and mature. We also highlight the importance of neutrophils, in addition to 
professional APCs monocytes and DCs, in the early response to MVA, unveil their high degree of phenotypic 
heterogeneity, and discover new subsets.
The transient mobilization of leukocytes was specific to the vaccine, since buffer injection did not result in 
such a dramatic effect. However, we cannot formally rule out a role played by the recombinant fusion protein HIV 
gag-pol-nef encoded in our vaccine.
The mild local adverse reaction is typical of subcutaneously administered vaccines and was expected for a 
non-replicating vaccine such as MVA. The subcutaneous injections of IMVAMUNE® or ACAM3000, which 
are third generation MVA vaccines against smallpox, have been described as safe, in contrast to replicating 
VACV which is more reactogenic44,45. The local reaction to VACV and MVA was reported to be stronger and 
longer-lasting for primary vaccinees than for non-naive participants, and after the first injection than after the 
second one44,46,47. This was also supported by our data on MVA vaccination in macaques.
We found that IL-6, MCP-1, and IP-10 plasma concentrations were altered after subcutaneous injections of 
cynomolgus macaques with MVA. The differences between post-prime and post-boost AUC were higher for 
IP-10. There are only limited in vivo studies on the early plasma cytokine response to MVA, contrary to in vitro 
data after restimulation of PBMCs or in vivo studies on earlier generation smallpox vaccines, for which cor-
relations between cytokine expression patterns and adverse events or vaccine take were identified. A study in 
rhesus macaques showed that IL-6 and IP-10 were the only cytokines for which levels increased in plasma one 
day after a single MVA intramuscular injection48. Comparison of serum cytokines after primary vaccination or 
re-vaccination with VACV in human volunteers showed that the peak levels were also statistically different for 
IP-10, in addition to IFNγ and MIG (CXCL9)49, which are induced by IFNγ and/or IFN type I and interact with 
the same receptor, CXCR343. Among many other soluble factors, IL-6, MCP-1, and IP-10 are produced in vitro in 
response to MVA by whole blood, PBMC, primary human monocytes and macrophages50,51, and the pathways 
involved have been elucidated51,52. The capacity of MVA to induce MCP-1 production distinguished it from other 
VACV strains50. Whether they are produced by infected cells and/or bystander cells53 is yet to be fully determined. 
Whether their presence in plasma originates from their release by cells from the injection site and/or from blood 
cells requires further investigation.
Beyond reactogenicity and plasma cytokine responses, the novelty of our study is the analysis of early innate 
cellular events after vaccination. Innate responses in blood or locally after injection of adjuvants or vaccines, 
including MVA, have been characterized in mice or macaques to better understand the mode of action of vac-
cines54–59. However, none of these studies analyzed the early cellular response to vaccines in the context of prime/
boost strategies. One seminal study54 compared distinct TLR adjuvants in rhesus macaques and demonstrated that 
Figure 6. Association of kinetic families with a direct biological measurement. (a) The relationship between 
kinetic family abundances and IP-10 plasma concentration was analyzed using linear regression. Iterative linear 
regressions were generated until all coefficients had a p-value ≤0.05. At each iteration, the coefficient having the 
highest p-value higher than 0.05 was removed. The differences between predicted vs. observed concentrations 
of IP-10 are shown. (b) The ELISA measured and linear regression predicted IP-10 concentrations are shown in 
a bi-plot representation. The Pearson correlation coefficient and p-value are indicated. (c) The linear regression 
coefficients of kinetic families III and VI, which are necessary and sufficient to predict IP-10 concentrations, are 
displayed along with their p-values.
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Figure 7. Visualization of and discrimination between post-prime and post-boost innate myeloid cell 
responses. (a) The Multidimensional Scaling (MDS) representation was calculated based on the abundance of 
each kinetic family. The Kruskal Stress is indicated and corresponds to the percentage of information lost during 
the dimensionality reduction process. Samples collected long before the prime injection (D-19PP) were not 
included. (b) Linear Discriminant Analysis (LDA) was performed after Least Absolute Shrinkage and Selection 
Operator (LASSO) (Supplementary Figure S11). Samples from the timepoints D-19PP, H0PP, and H0PB were 
not used for this analysis. The LDA scores of each sample are shown. The LDA score indicated whether a given 
sample was classified as post-prime (positive score) or post-boost (negative score). The samples colored in blue 
correspond to post-prime samples and the samples colored in red correspond to post-boost samples. (c) The 
LDA coefficients for each kinetic family are shown. (d–f) Kolmogorov-Smirnov (KS) distances of expression 
distribution densities were computed for each marker for neutrophils, cDCs, and monocytes (Supplementary 
Figure S12). This distance corresponds to the maximal difference between the distributions of marker 
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they differentially stimulated systemic immune responses. The intensity quality and kinetics of blood cells enrich-
ment were specific of each adjuvant. MPL, R848, and CpG ODN induced a rapid increase of blood neutrophils and 
CD14+ monocytes. However, neutrophil counts reached a higher level with R848 and two successive neutrophil 
expansions were observed with CpG ODN. In addition, only R848 and CpG ODN mobilized the intermediate 
CD14+CD16+ followed by non-classical CD14dimCD16high monocytes and mediated pDCs and cDCs activation.
We identified potential new subsets of innate myeloid cells. There were more CD4highCD23highCD11chigh neu-
trophils after the boost than the prime. They are likely linked to inflammation27–29, and may exert regulatory/
suppressive effects. CD66highCD32highCD11bhighCD45highCCR7highIL-10high neutrophils were also more highly 
enriched after the boost than the prime37. They may have a critical role in the resolution of infection upon the 
second encounter with pathogens. As previously described10,60–63, we observed a population of cells sharing cDC 
and monocyte phenotypic patterns (CD11chighCD16highCD11ahighCD14highCD45highIP-10mid/high), which we des-
ignated inflammatory cDCs/non-classical monocytes. This pro-inflammatory cell type expanded more after the 
boost than the prime. We also identified HLA-DRlow monocytes and cDCs, which are likely immature or immu-
nosuppressive. Comparative functional analyses are required for their definitive classification as new subsets. In 
future studies, a refined panel should also include antibodies targeting additional markers, such as CD1c, CD141, 
CD172a, CD33, CD45RA and SIGLEC6, to clearly distinguish DC precursors from pDCs, separate the various 
cDC and monocyte subtypes, and identify myeloid-derived suppressive cells (MDSCs)24,64–66.
Innate immune responses differ after one and two immunizations, as adaptive immune responses do. There are 
many possible reasons for this difference which are yet to be tested. At the boost, there were antibodies directed 
against MVA, contrary to the prime18. The vaccine was probably rapidly cleared and sensed differently, not as free 
viral particles, but as immune complexes. A different sensing could translate into a different alarm. It was recently 
shown, using mass cytometry, that the activation of signaling pathways and cytokine production by blood innate 
myeloid cells in response to the split influenza vaccine was dependent on immune complex formation and CD16 
and CD32 FcγR activation67. Several studies, based on monoclonal antibody therapies, have also reported the impor-
tance of immune complexes and Fc receptor engagement in enhanced protective immune responses and vaccine-like 
effect7. This would be consistent with the higher expression of the FcR (CD16 and CD32) we observed among blood 
neutrophils, monocytes, and cDCs responding to the boost. Local memory cells established after the first immuni-
zation could also have played a role in the different innate myeloid responses after one and two immunizations. It has 
been shown in mice that IFNγ and MIP-1α produced by memory T cells after antigen recognition resulted in faster 
activation and recruitment of innate cells as well as better killing capacities by phagocytes68,69. In addition, TNFα 
produced by resident memory CD8+ T cells was reported to induce local DC maturation70. The induction of resident 
CD8+ T cells in the skin has been demonstrated in mice after MVA71 and VACV skin infection72,73. Finally, trained 
innate immunity5 could participate in the different innate immune responses during prime/boost immunizations, 
assuming that trained cells survive long enough between the two immunizations. Tissue-resident macrophages and/
or cells recruited from blood or their progenitors after the prime could be involved.
Conversely, the different innate responses after the prime and boost may affect the restimulation of primary 
memory B and T cells and their differentiation into secondary memory cells. Neutrophils the most specific for the 
post-boost response expressed higher levels of CD66, which plays a role in adhesion and interactions with DCs74, 
and of IL-8, a key chemoattractant of neutrophils to the site of inflammation and inducer of phagocytosis75. 
Neutrophils expanding after the boost also produced more IL-10. Immunosuppressive IL-10 producing neu-
trophils have been reported in mice76,77, whereas their presence in humans is more controversial78. Finally, neu-
trophils recruited after the boost expressed a higher level of CCR7, suggesting their capacity to migrate directly 
to lymph node37,79. cDCs and monocytes, and to a lesser extent neutrophils, participating in the early response 
after the boost expressed higher levels of HLA-DR, involved in antigen presentation to CD4+ T cells, and IL-12, 
promoting Th1 development and controlling the CD8+ T cell response80. Neutrophils, cDCs, and monocytes 
mobilized after the boost were more prone to phagocytosis with higher expression of FcR (CD32 and CD16) 
and integrins CD11a, CD11b and CD11c, which are also involved in tissue-specific homing of leukocytes during 
inflammation and leukocyte activation81,82. Monocytes were more activated, as they expressed a higher level of 
CD14, which acts as PRR83, and IP-10. cDCs were also more mature, with a higher expression of CXCR4 and 
CCR5, which allow their trafficking to the vaccine injection site and its draining lymph node84,85. Finally, innate 
myeloid cells elicited after the boost were more responsive with higher expression of CD45. CD45 is well known 
to lower the threshold of BCR and TCR signaling on B and T cells. It was also shown to regulate FcR, TLR, and 
cytokine signaling in phagocytes and DCs, as well as neutrophils migration86. Overall, better antigen uptake 
and presentation is more likely after the boost than after prime, contributing to enhanced T cells restimulation, 
although the requirements of signal 1 (TCR stimulation), 2 (co-stimulation), and 3 (inflammatory cytokines) 
differ between naive and memory T cells activation87.
Whether the observed differences between the early response to the first and second vaccine injections also 
hold true for innate lymphoid cells needs to be tested. Additionally, it is important to define what is MVA-specific 
from what is shared with other vaccines. Another challenge will be to determine predictive correlations between 
innate and adaptive responses in the context of prime/boost immunizations, as previously done for one-dose vac-
cines88, or yearly influenza vaccine89. Nonetheless, the differential innate responses described here can be valuable 
to tailor vaccine-induced immunity.
expression in the two compared cell populations. KS distance is commonly used in flow cytometry analyses93. 
MSI histograms for the top 8 markers with the highest KS distance are displayed for (d) neutrophils, (e) cDCs, 
and (f) monocytes from kinetic families that discriminate between the post-prime (blue) and the post-boost 
responses (red) as defined in Fig. 7c. Histograms were built on the whole dataset and did not represent a 
particular sample (animal or timepoint).
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Methods
Ethics statement. This experiment was approved by the «Ministère de l’Éducation Nationale, de 
l’Enseignement Supérieur et de la Recherche» (France) and the ethical committee «Comité d'éthique en 
expérimentation animale n°44» (France) under the reference 201503131451825402 (APAFIS#319) and 
2015062215324227v1(APAFIS#891) for Figure S2. Animals were handled by veterinarians in accordance with 
national regulations (CEA Permit Number A 92–32–02) and the European Directive (2010/63, recommendation 
N°9) and in compliance with Standards for Human Care and Use of Laboratory of the Office for Laboratory 
Animal Welfare (OLAW, USA) under OLAW Assurance number #A5826-01.
Vaccine, animals, and blood samples. The ANRS recombinant MVA HIV B vaccine (MVATG17401; 
Transgene, Illkirch-Graffenstaden, France) was injected subcutaneously into five cynomolgus macaques, at 
4 × 108 PFU, two months apart as previously described18. It contains the full-length codon-optimized sequence 
of gag (encoding amino acids [aa] 1 to 512) fused with fragments from pol (encoding aa 172 to 219, 325 to 383, 
and 461 to 519) and nef (encoding aa 66 to 147 and 182 to 206) from the Bru/Lai isolate (Los Alamos data-
base accession number K02013). Blood samples were collected longitudinally in EDTA, to count leukocytes, or 
Lithium-Heparin to measure soluble plasma factors and perform single-cell mass cytometry analyses.
For Figure S2, six macaques were injected subcutaneously with a buffer containing 10 mM Tris-HCl, saccha-
rose 5% (w/v), 10 mM NaGlu, 50 mM NaCl, pH8.0 and one month later with the same dose and batch of MVA 
HIV B as the other five animals.
Quantification of plasma soluble factors. C-reactive protein (CRP) was quantified in plasma by 
Laboratoire Vébio (Arcueil, France) using an immunoturbidimetry assay (CRP Plus, Thermo Scientific). 
Cytokine, chemokine and growth factor levels were assessed with a multiplex immunoassay (MILLIPLEX MAP 
non-human primate cytokine magnetic bead panel, Millipore), except plasma IP-10 concentrations, which were 
assessed by ELISA (human CXCR10/IP-10, R&D systems). Post-prime (PP) and post-boost (PB) samples were 
assessed independently.
Staining, mass cytometry acquisition, and data processing. Blood processing, staining, and acquisi-
tion using a CyTOF (Fluidigm), as well as initial leukocyte gating, were performed as previously described10. Briefly, 
1 mL of blood was incubated with a fixation mixture containing PFA and glycerol10,90 for 10 min at 4 °C. After centrif-
ugation, erythrocytes were lysed in 10 mL of milli-Q water at room temperature for 20 min. Cells were then washed 
in DPBS 1× and stored at −80 °C at a final concentration of 15 · 106 cells in the fixation mixture. Three millions of 
fixed leukocytes were thawed. After 2 washes with PBS/BSA at 0.5%, they were incubated with the surface antibod-
ies at 4 °C for 30 min (Supplementary Table S3). They were washed twice in PBS 1× and fixed in PBS/PFA 1.6% for 
20 min RT. After permeabilization in Perm/Wash Buffer 1× (BD Biosciences) for 10 min at RT, cells were incubated 
with intracellular antibodies at 4 °C for 30 min (Supplementary Table S3). Finally cells were washed in PBS and 
incubated overnight with 0.1 µM of iridium RNA/DNA intercalator in PBS/PFA at 1.6%. The next day, cells were 
washed three times with milli-Q water and filtered using a 35 µm nylon mesh cell stainer (BD Biosciences). EQTM 
four elements calibration beads (Fluidigm, San Fransisco, USA) were added following manufacturer’s protocol. Each 
sample was divided into two replicates and acquisition was performed using the autosampler device for CyTOF 
(both from DVS Fluidigm). 5 stainings/acquisitions were done (one per animal) using the same batch of antibodies 
each time. In addition, we followed an established strategy91 to control the quality of each staining/acquisition and 
their reproducibility by including the same two control samples (Supplementary Figure S13).
Automatic identification of cell populations. Cell populations were identified using the Spanning-tree 
Progression Analysis of Density-normalized Events (SPADE) algorithm19. Briefly, a random pre-downsampling 
was used to select 60,000 cells from each sample (60,000 corresponded to the number of cells contained in the 
smallest sample -Table S5). Then the SPADE algorithm per se was applied to all samples (all macaques and all 
timepoints) to define the phenotype of each cluster as well as the topology of the tree. Full upsampling was even-
tually performed.
For our dataset, the optimal SPADE settings were determined with SPADEVizR package20 as 20 clustering 
markers (CD66, HLA-DR, CD3, CD64, CD8, CD123, CD11a, CD11b, CD4, CD23, CD86, CD32, CXCR4, CCR5, 
CD16, CD11c, CD14, CD45, CD20 and CCR7), 600 clusters, a density-based downsampling of 10%, and an 
outlier density parameter of 0.01. The clustering quality was expressed as the percentage of clusters displaying a 
unimodal and narrow distribution of all clustering markers, as well as the percentage of small clusters (clusters 
with less than 50 cells in total). Markers distributions were assessed using the Hartigan’s dip test (p-value < 0.05 
to reject the uni-modality hypothesis). Markers distributions with an interquartile range (IQR) < 2 were consid-
ered to be narrow. These settings resulted in the highest percentage of uniform clusters and the absence of small 
clusters. Numbers and percentages of non-uniform clusters for each marker are displayed in Table S6.
Leukocyte counts, absolute number calculation, and abundance profiles. The leukocyte counts 
were quantified using an HmX instrument (Beckman Coulter). The absolute number of cells in a population was 
computed as: N = the absolute number of leukocytes expressed per μL of blood x number of cells in the popu-
lation detected by the CyTOF/total number of leukocytes (defined as non CD3+CD66+ cells) detected by the 
CyTOF. The absolute number kinetics was called the abundance profile.
Heatmap representations of the cell cluster phenotypes. Heatmaps of the cell cluster phenotypes 
were generated using SPADEVizR20. The mean of the median of the mean signal intensity (MSI) for each marker 
among samples was displayed according to five phenotypic bins calculated by dividing the marker range of 
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expression between the 5th and the 95th percentile into five categories for all cell clusters. For each cluster, samples 
contributing less than 10 cells were excluded. Hierarchical clusterings of cell clusters and markers were performed 
using the Euclidean metric based on the ward.D linkage.
Phenotypic and kinetic families. Cell clusters sharing similar phenotypes were gathered into phenotypic 
families based on the cluster dendrogram. Phenotypic families sharing similar dynamics were gathered into 
kinetic families based on their abundance profiles. This determination was performed using SPADEVizR20 with 
the hierarchical method based on the Pearson correlation and complete linkage.
Statistical tests. Soluble factor concentrations and cell abundances were compared between timepoints 
using the permutation test available in the “exactRankTests” R package. The area under the curve (AUC) cor-
responds to the sum over time of all plasma soluble factor concentrations (cumulated concentration) or cell 
abundances (cumulated abundance) between H3 and D14. PP AUC and PB AUC were compared using the per-
mutation test. Correlation analyses were performed using the Pearson coefficient. The density distributions of 
markers were compared using the Kolmogorov-Smirnov distance using CytoCompare92.
Modeling. The linear regression model was constructed using SPADEVizR20. The abundance profiles of 
kinetic families were used as the entry parameter and IP-10 concentration as the biological value to predict. The 
validity of the model was assessed by excluding either one sample or one individual and by comparing predicted 
and observed values.
Discrimination between post-prime and post-boost innate myeloid responses. The Least 
Absolute Shrinkage and Selection Operator (LASSO) approach was performed on R using the “lars” package. 
Centered and reduced abundance profiles of kinetic families were used as entry parameters. The validity of clas-
sification at each iteration was assessed by cross-validation. The best configuration was chosen as the lowest 
number of kinetic families used and the lowest error rate in cross-validation. Linear Discriminant Analysis (LDA) 
was performed on R with the “MASS” package based on the abundance profiles of kinetic families and classes 
(post-prime or post-boost) as entry parameters.
Data availability and interactivity. Mass cytometry data were deposited publicly. FCS files are available 
on the FlowRepository database through ID FR-FCM-ZYBG, and the Cytobank platform under accession num-
bers 68443 and 68590. The http://data.idmitcenter.fr/MVA-innate-myeloid/ website provides interactive SPADE 
quality control data, interactive SPADE trees, interactive heatmaps, and interactive histograms. The interactive 
heatmaps avoid to juggle between Fig. 4 (heatmaps), Supplementary Figures S8–9 (phenotypic families abun-
dance profiles), Fig. 5a (kinetic families), Table 1 (correspondance between phenotypic and kinetic families), and 
Fig. 7c (kinetic families LDA selection). They directly connect clusters and phenotypic families to their annota-
tion, kinetic families, and their relevance as signature of the response to a first or a second immunization.
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